Nicholas Cheng is using data to compare over 400 OHS participants who’ve experienced a cancer diagnosis, with matched cancer-free participants, to look for biomarkers in the blood that could be used to detect breast, prostate and pancreatic cancers several years before a traditional diagnosis. Hear what motivates this PHD student, as he reflects on his

A new funding opportunity from the CIHR Institute of Cancer Research (CIHR-ICR) is available and provides up to $500,000 to use provincial data from the OHS, or to use pan-Canadian data from the Canadian Partnership for Tomorrow’s Health (CanPath). Up to $100,000 over one year will be awarded for a single grant. The goal of

Nicholas Cheng provides an overview of his study on identifying early cancer biomarkers in pre-diagnosis blood samples collected from more than 400 OHS participants. He demonstrates how blood signatures can be used to detect breast, prostate and pancreatic cancers years prior to clinical detection using cfDNA methylation profiles. Kimberly Skead describes her work studying how the interacting